Skip to content
MedsAcross

Medicine

Neomycin and Polymyxin B Sulfates and Dexamethasone 1 mg/3.5 mg/10000 units per mL ophthalmic suspension

Available on requestPrescription onlyUS FDA

Neomycin and Polymyxin B Sulfates and Dexamethasone 1 mg/3.5 mg/10000 units per mL ophthalmic suspension is a prescription medicine containing Dexamethasone, Neomycin and Polymyxin b for ophthalmic use, marketed by Sandoz, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store upright at 8° - 27°C (46° - 80° F).

Key facts

Active ingredient (INN)
Dexamethasone, Neomycin and Polymyxin b
Brand
Neomycin and Polymyxin B Sulfates and Dexamethasone
Strength
1 mg/3.5 mg/10000 units per mL
Dosage form
Ophthalmic suspension
Route
Ophthalmic
Packs
5 mL
Marketing authorisation holder
Sandoz
Manufacturers
SandozNuCare Pharmaceuticals,Inc
Origin register
US FDA, United States
Storage
Store upright at 8° - 27°C (46° - 80° F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
21 February 1996
Identifiers
RxCUI 309680DailyMed set ID 54da7bef-c3b0-4353-e054-00144ff8d46c, cf1a6da8-ba79-4bff-a13b-6effb67f6c1cNDC 68071-3359, 61314-630Application ANDA062341

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
5 mL in 1 bottle, plastic61314-630-06Sandoz21 February 1996
5 mL in 1 box68071-3359-5NuCare Pharmaceuticals,Inc21 July 2017

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 6 June 1963Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Dexamethasone, Neomycin and Polymyxin b 1 mg/3.5 mg/10000 units per mL ophthalmic suspension.

Compare all 3

Other strengths and forms of Dexamethasone, Neomycin and Polymyxin b

Clinical summary

Dexamethasone, Neomycin and Polymyxin b is a fixed-dose combination of an aminoglycoside antibacterial, a corticosteroid and a polymyxin-class antibacterial indicated and where bacterial infection or a risk of bacterial infection exists. MedsAcross supplies Dexamethasone, Neomycin and Polymyxin b for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Dexamethasone, Neomycin and Polymyxin b

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Neomycin and Polymyxin B Sulfates and Dexamethasone 1 mg/3.5 mg/10000 units per mL ophthalmic suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.